Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.
Adult
Aged
Drug Administration Schedule
Female
Humans
Immunologic Factors
/ adverse effects
Kaplan-Meier Estimate
Lenalidomide
/ adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell
/ drug therapy
Male
Middle Aged
Multivariate Analysis
Neutropenia
/ etiology
Progression-Free Survival
Receptors, Notch
/ metabolism
Recurrence
Rituximab
/ adverse effects
Treatment Outcome
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
14 05 2019
14 05 2019
Historique:
received:
09
01
2019
accepted:
26
03
2019
entrez:
12
5
2019
pubmed:
12
5
2019
medline:
12
5
2020
Statut:
ppublish
Résumé
This phase 2 study was conducted to prospectively evaluate how clinical and biological factors correlate with outcome in patients with treatment-naive (TN) and relapsed (R) chronic lymphocytic leukemia (CLL) treated with lenalidomide and rituximab. Oral lenalidomide 10 mg was administered daily starting on day 9 of cycle 1. IV rituximab 375 mg/m
Identifiants
pubmed: 31076409
pii: bloodadvances.2019031336
doi: 10.1182/bloodadvances.2019031336
pmc: PMC6517659
doi:
Substances chimiques
Immunologic Factors
0
Receptors, Notch
0
Rituximab
4F4X42SYQ6
Lenalidomide
F0P408N6V4
Banques de données
ClinicalTrials.gov
['NCT01446133']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533-1539Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2019 by The American Society of Hematology.
Références
Lancet Haematol. 2017 Nov;4(11):e534-e543
pubmed: 28958469
Br J Haematol. 2015 Oct;171(2):281-284
pubmed: 25824652
J Clin Oncol. 2015 Sep 1;33(25):2803-11
pubmed: 26195701
Immunity. 2003 Feb;18(2):301-12
pubmed: 12594956
Biomed Res Int. 2014;2014:265840
pubmed: 25313353
Clin Cancer Res. 2008 Jul 15;14(14):4650-7
pubmed: 18628480
Leukemia. 2018 Oct;32(10):2278-2281
pubmed: 29479067
Blood. 2018 Apr 19;131(16):1820-1832
pubmed: 29358183
Blood. 2013 Aug 1;122(5):734-7
pubmed: 23801633
J Clin Invest. 2008 Jul;118(7):2427-37
pubmed: 18551193
Haematologica. 2017 Dec;102(12):e494-e496
pubmed: 28798068
Blood. 2010 Apr 1;115(13):2619-29
pubmed: 19965642
Blood. 2008 Jun 1;111(11):5291-7
pubmed: 18334676
J Clin Oncol. 2011 Mar 20;29(9):1175-81
pubmed: 21189385
Haematologica. 2012 Mar;97(3):328-30
pubmed: 22383743
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Haematologica. 2015 Feb;100(2):253-62
pubmed: 25398834
J Clin Oncol. 2013 Feb 10;31(5):584-91
pubmed: 23270003
Nature. 2015 Oct 22;526(7574):525-30
pubmed: 26466571
J Clin Oncol. 2014 Jul 1;32(19):2067-73
pubmed: 24868031
Leuk Res. 2016 Aug;47:78-83
pubmed: 27285853
EMBO J. 2002 Oct 15;21(20):5417-26
pubmed: 12374742
J Clin Oncol. 2006 Dec 1;24(34):5343-9
pubmed: 17088571
Expert Opin Investig Drugs. 2017 May;26(5):633-650
pubmed: 28388253
Lancet Haematol. 2017 Oct;4(10):e475-e486
pubmed: 28916311
Biochim Biophys Acta. 2005 May 25;1729(1):50-6
pubmed: 15777657
Blood. 2011 Sep 29;118(13):3489-98
pubmed: 21725050